Search results
Oct 1, 2020 · In this review, we point out the main challenges and the strategies to specifically address the problems that need to be surmounted in the push toward a therapeutic application of miRNAs. Particular emphasis is given to approaches that have already found their way into clinical studies.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
View Michael Y. Chow’s profile on LinkedIn, a professional community of 1 billion members. Experience: XRM Media · Education: The University of Texas at Austin · Location: Los Angeles · 500...
- 500+
- Los Angeles, California, United States
- XRM Media
University College London School of Pharmacy - Cited by 2,440 - Pharmaceutics - Pulmonary Drug Delivery
They eventually formed a relationship with strategic partner Michael Y. Chow, co-founder of XRM Media, a media technology company targeting Generation Z and millennial audiences, and managing partner of MNM Creative, a multi-media and entertainment company with offices in Shanghai and China.
Sep 4, 2020 · The studies are classified by (A) type of delivery vector; (B) disease model used; (C) administration method used in animal studies; and (D) RNA type. The classification was done independently by Y.Q. and M.C. and was cross-validated by J.K.W.L. Abbreviation: LIRI, lung ischemia–reperfusion injury.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
Abstract. Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different from antibiotics and the lack of understanding potentially limits ...
Michael Y.T. Chow's 33 research works with 1,650 citations and 21,161 reads, including: Delivery technology of inhaled therapy for asthma and COPD
